- Language: English
- 1016 Pages
- Published: October 2012
Global Lung Cancer Therapeutics Market 2012-2016
- ID: 2408115
- January 2013
- Region: Global
- 55 pages
TechNavio's analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 13.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Lung Cancer Therapeutics market in the US. The Global Lung Cancer Therapeutics market has also been witnessing an increase in the number of MandAs. However, the adversative side effects of lung cancer therapeutic drugs could pose a challenge to the growth of this market.
TechNavio's report, the Global Lung Cancer Therapeutics Market 2012-2016, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG.
The other vendors mentioned in the report are Ambit Biosciences Inc., ARIAD Pharmaceuticals Inc., Biogen Idec Inc., Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd., ERYtech Pharma SA, Genmab A/S, Genzyme Corp., Pfizer Inc., Sunesis Pharmaceuticals Inc., Talon Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors? SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
04.1 Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Hoffmann-La Roche Ltd.
15.2 Eli Lilly and Co.
15.3 Sanofi S.A.
15.4 Bristol-Myers Squibb Co.
15.5 AstraZeneca plc
15.6 Novartis AG
15.7 GlaxoSmithKline plc
16. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Lung Cancer Therapeutics Market 2012-2016 (US$ billion)
Exhibit 2: Global Lung Cancer Therapeutics Market by Geographical Segmentation 2012
Exhibit 3: Global Lung Cancer Therapeutics Market by Vendor Segmentation 2012
Exhibit 4: Global Lung Cancer Therapeutics Market by Leading Drugs Segmentation 2012
Exhibit 5: Business Segmentation of Hoffmann-La Roche Ltd.
Exhibit 6: Business Segmentation of Eli Lilly and Co.
Exhibit 7: Business Segmentation of Sanofi S.A.
Exhibit 8: Business Segmentation of Bristol-Myers Squibb Co.
Exhibit 9: Business Segmentation of AstraZeneca plc
Exhibit 10: Business Segmentation of Novartis AG
Exhibit 11: Business Segmentation of GlaxoSmithKline plc
TechNavio Announces the Publication of its Research Report - Global Lung Cancer Therapeutics Market 2012-2016
TechNavio today launched its report, Global Lung Cancer Therapeutics Market 2012-2016, based on an in-depth analysis covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers' understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio's Healthcare team said: ''There has been an increase in medical tourism in the APAC region. Patients from all around world are visiting countries such as China and India for treatments. The healthcare facilities in the APAC region are improving, with excellent healthcare providers providing better treatment for diseases such as cancer or any other treatment at a low cost. Thus, the increase in the number of patients coming to China and India for cancer treatment is a growing trend, which is encouraging the healthcare organizations to opt for more lung cancer therapeutic drugs.''
According to the report, one of the major growth factors driving the Global Lung Cancer Therapeutics market is the increase in the prevalence of cancer patients worldwide. Therapeutic drugs are among the remedies for cancer, and hence healthcare organizations are opting for lung cancer therapeutic drugs for treatments. Moreover, most of the vendors are focusing significantly on the US market, which is expected to witness a faster growth rate than the global CAGR during the period 2012-2016.
Further, the report reveals that one of the major challenges in this market is the delays in diagnosing cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.